JP2010501191A5 - - Google Patents

Download PDF

Info

Publication number
JP2010501191A5
JP2010501191A5 JP2009525967A JP2009525967A JP2010501191A5 JP 2010501191 A5 JP2010501191 A5 JP 2010501191A5 JP 2009525967 A JP2009525967 A JP 2009525967A JP 2009525967 A JP2009525967 A JP 2009525967A JP 2010501191 A5 JP2010501191 A5 JP 2010501191A5
Authority
JP
Japan
Prior art keywords
fusion protein
component
nucleic acid
protein according
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009525967A
Other languages
English (en)
Japanese (ja)
Other versions
JP5274464B2 (ja
JP2010501191A (ja
Filing date
Publication date
Priority claimed from EP06017891A external-priority patent/EP1894940A1/en
Application filed filed Critical
Publication of JP2010501191A publication Critical patent/JP2010501191A/ja
Publication of JP2010501191A5 publication Critical patent/JP2010501191A5/ja
Application granted granted Critical
Publication of JP5274464B2 publication Critical patent/JP5274464B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009525967A 2006-08-28 2007-08-28 Tnfスーパーファミリー融合タンパク質 Expired - Fee Related JP5274464B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06017891.0 2006-08-28
EP06017891A EP1894940A1 (en) 2006-08-28 2006-08-28 TNF superfamily fusion proteins
PCT/EP2007/007517 WO2008025516A2 (en) 2006-08-28 2007-08-28 Tnf superfamily fusion proteins

Publications (3)

Publication Number Publication Date
JP2010501191A JP2010501191A (ja) 2010-01-21
JP2010501191A5 true JP2010501191A5 (https=) 2010-07-15
JP5274464B2 JP5274464B2 (ja) 2013-08-28

Family

ID=37836940

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009525967A Expired - Fee Related JP5274464B2 (ja) 2006-08-28 2007-08-28 Tnfスーパーファミリー融合タンパク質

Country Status (8)

Country Link
US (2) US8147843B2 (https=)
EP (2) EP1894940A1 (https=)
JP (1) JP5274464B2 (https=)
AT (1) ATE505481T1 (https=)
AU (1) AU2007291490A1 (https=)
CA (2) CA2860945C (https=)
DE (1) DE602007013920D1 (https=)
WO (1) WO2008025516A2 (https=)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2176288B1 (en) 2007-07-10 2015-11-04 Apogenix GmbH Tnf superfamily collectin fusion proteins
EP2540740B1 (en) * 2008-06-17 2014-09-10 Apogenix GmbH Multimeric TNF receptors
US20110189194A1 (en) * 2008-07-14 2011-08-04 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Use of cd95 inhibitors for the treatment of inflammatory disorders
DK2604693T3 (en) 2008-07-21 2016-05-30 Apogenix Gmbh Single-chain TNFSF molecules
JP5844158B2 (ja) 2009-01-09 2016-01-13 アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングApogenix GmbH 三量体形成融合タンパク質
TWI476001B (zh) 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Fc融合蛋白及其用途
AU2013295647B2 (en) 2012-07-26 2018-02-08 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Multimeric fusion protein vaccine and immunotherapeutic
WO2014100913A1 (en) * 2012-12-24 2014-07-03 Beijing Anxinhuaide Biotech. Co., Ltd Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
NO2776305T3 (https=) 2014-04-23 2018-01-27
BR102014031185A8 (pt) * 2014-12-12 2021-05-04 Fund De Amparo A Pesquisa Do Estado De Sao Paulo Fapesp proteína recombinante indutora da apoptose; processo de obtenção da dita proteína e o seu uso no tratamento do câncer
PT3247728T (pt) 2015-01-20 2020-07-16 Igm Biosciences Inc Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
EP3076179A1 (en) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnosis and treatment of low grade gliomas
AU2016325482B2 (en) 2015-09-23 2020-09-03 Apogenix Ag Anti-CD95L antibody
EP3374504B1 (en) * 2015-11-09 2025-03-19 CureVac SE Optimized nucleic acid molecules
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
CA3049165A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
BR112019013940A2 (pt) 2017-01-06 2020-02-11 Iovance Biotherapeutics, Inc. Método de tratar um câncer com uma população de linfócitos infiltrantes de tumor, processo para preparação de uma população de linfócitos infiltrantes de tumor, população de linfócitos infiltrantes de tumor, e, composição farmacêutica.
US20200224161A1 (en) 2017-05-10 2020-07-16 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
EP3635097A1 (en) 2017-06-05 2020-04-15 Iovance Biotherapeutics, Inc. Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
EP3664832B1 (en) * 2017-08-11 2023-10-18 The Board of Trustees of the University of Illinois Truncated guinea pig l-asparaginase variants and methods of use
EP4501408A3 (en) 2017-11-17 2025-04-09 Iovance Biotherapeutics, Inc. Til expansion from fine needle aspirates and small biopsies
EP3714041A1 (en) 2017-11-22 2020-09-30 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
EP3724885A2 (en) 2017-12-15 2020-10-21 Iovance Biotherapeutics, Inc. Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
SG11202006541UA (en) 2018-01-08 2020-08-28 Iovance Biotherapeutics Inc Processes for generating til products enriched for tumor antigen-specific t-cells
CA3090795A1 (en) 2018-02-13 2019-08-22 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
MA52667B1 (fr) 2018-03-29 2024-07-31 Iovance Biotherapeutics, Inc. Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie
US20210130779A1 (en) 2018-04-27 2021-05-06 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2019217753A1 (en) 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
US20220275043A1 (en) 2018-07-17 2022-09-01 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療
CA3112599A1 (en) 2018-09-20 2020-03-26 Iovance Biotherapeutics, Inc. Expansion of tils from cryopreserved tumor samples
US20230039976A1 (en) 2018-11-05 2023-02-09 Iovance Biotherapeutics, Inc. Selection of improved tumor reactive t-cells
TW202039831A (zh) 2018-11-05 2020-11-01 美商艾歐凡斯生物治療公司 對抗pd-1抗體呈現難治性之非小細胞肺癌(nsclc)病患之治療
TW202039830A (zh) 2018-11-05 2020-11-01 美商艾歐凡斯生物治療公司 用於製造腫瘤浸潤性淋巴細胞之方法及其在免疫療法中之用途
CA3118493A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
JP7710372B2 (ja) 2018-12-19 2025-07-18 アイオバンス バイオセラピューティクス,インコーポレイテッド 操作されたサイトカイン受容体対を使用して腫瘍浸潤リンパ球を拡大培養する方法及びその使用
US20220133795A1 (en) 2019-03-01 2022-05-05 Iovance Biotherapeutics, Inc. Expansion of Tumor Infiltrating Lymphocytes From Liquid Tumors and Therapeutic Uses Thereof
CA3134144A1 (en) 2019-03-29 2020-10-08 Myst Therapeutics, Llc Ex vivo methods for producing a t cell therapeutic and related compositions and methods
US20220249559A1 (en) 2019-05-13 2022-08-11 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
JP2022553389A (ja) 2019-10-25 2022-12-22 アイオバンス バイオセラピューティクス,インコーポレイテッド 腫瘍浸潤リンパ球の遺伝子編集及び免疫療法におけるその使用
CA3162703A1 (en) 2019-11-27 2021-06-03 Myst Therapeutics, Llc Method of producing tumor-reactive t cell composition using modulatory agents
US12516291B2 (en) 2019-12-11 2026-01-06 Iovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
JP7817937B2 (ja) 2020-02-27 2026-02-19 ターンストーン バイオロジクス コーポレイション 腫瘍反応性t細胞のエクスビボ富化および増大のための方法ならびに関連するその組成物
EP4146794A1 (en) 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
TW202208616A (zh) 2020-05-04 2022-03-01 美商艾歐凡斯生物治療公司 改良之腫瘤反應性t細胞的選擇
JP2023538667A (ja) * 2020-08-24 2023-09-08 サノフィ パスツール インコーポレイテッド Sars-cov-2感染症に対するワクチン
US20230372397A1 (en) 2020-10-06 2023-11-23 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
TW202241468A (zh) 2020-12-11 2022-11-01 美商艾歐凡斯生物治療公司 用腫瘤浸潤性淋巴球療法與braf抑制劑及/或mek抑制劑組合治療癌症患者
CA3202483A1 (en) 2020-12-17 2022-06-23 Maria Fardis Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
US20240123067A1 (en) 2020-12-17 2024-04-18 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocyte therapies
CA3207359A1 (en) 2021-02-05 2022-08-11 Cecile Chartier-Courtaud Adjuvant therapy for cancer
WO2022187741A2 (en) 2021-03-05 2022-09-09 Iovance Biotherapeutics, Inc. Tumor storage and cell culture compositions
AU2022246174A1 (en) 2021-03-25 2023-09-14 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
EP4326287A2 (en) 2021-04-19 2024-02-28 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2022245754A1 (en) 2021-05-17 2022-11-24 Iovance Biotherapeutics, Inc. Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
KR20240013766A (ko) * 2021-05-27 2024-01-30 베이징 안신화이더 바이오텍. 씨오., 엘티디 2개의 trail 삼량체를 포함하는 수퍼-trail 분자
US20240342285A1 (en) 2021-07-28 2024-10-17 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
EP4404969A1 (en) 2021-09-24 2024-07-31 Iovance Biotherapeutics, Inc. Expansion processes and agents for tumor infiltrating lymphocytes
WO2023077015A2 (en) 2021-10-27 2023-05-04 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
EP4430167A1 (en) 2021-11-10 2024-09-18 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
US20250101380A1 (en) 2022-01-28 2025-03-27 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
CA3248034A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT
EP4565683A1 (en) 2022-08-01 2025-06-11 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2410525A1 (en) * 2000-05-26 2001-11-29 Mochida Pharmaceuticals Co., Ltd. Fas ligand-fused proteins

Similar Documents

Publication Publication Date Title
JP2010501191A5 (https=)
US12060401B2 (en) Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders
JP7128246B2 (ja) 抗炎症活性を有するペプチド、及びそれを含む組成物
JP6545759B2 (ja) アゴニストおよびアンタゴニストとしての循環置換により修飾されるリガンド
CN100385002C (zh) 重组融合蛋白的二聚体、三聚体、四聚体或五聚体的二聚物或寡聚物
JP5274464B2 (ja) Tnfスーパーファミリー融合タンパク質
JP2021501581A5 (https=)
HRP20150425T1 (hr) Tnf sf jednolanäśane molekule
FI3368555T3 (fi) Kaksitoimisia proteiineja ja niitä sisältävä farmaseuttinen koostumus
WO2009149171A4 (en) Fgf21 mutants and uses thereof
CN104470944A (zh) 非天然共有白蛋白结合结构域
JP2018533947A5 (https=)
Yuan et al. Production of recombinant human interleukin-38 and its inhibitory effect on the expression of proinflammatory cytokines in THP-1 cells
CA2894219C (en) Novel interleukin-33 inhibitors
JP2020519230A5 (https=)
JP2014513920A (ja) 新規な超活性il−33断片およびその使用
JP5462623B2 (ja) Elr−cxcケモカインの高親和性アンタゴニスト
JP6320973B2 (ja) B細胞活性化因子の拮抗物質、その調製方法及び利用法
US7820622B2 (en) TNF antagonists
KR101955366B1 (ko) 인터페론 베타-엘라스틴 재조합 단백질 및 이의 생산방법
Pyo et al. Expression and purification of a recombinant buforin derivative from Escherichia coli
EP2597102A1 (en) A novel fusion protein comprising an antibody light chain and a polypeptide binding to IL-17
JP2009536821A5 (https=)
JPWO2021229076A5 (https=)
JP5385611B2 (ja) Pf4とrantesとの相互作用に対するアンタゴニスト